All News
Exciting phase 2 data on bimekizumab (dual anti-17A and F) in r-axSpA, looks like 160mg is the go, I hear on the grapevine that they are well into phase 3. Looking forward to the results #ACR19 @RheumNow Abs 3S111 https://t.co/PTCgjWm2EM
Philip Robinson philipcrobinson ( View Tweet)
Previous smoking hx increase risk of UC, but this goes into remission almost immediately when they resume smoking...“The good thing about that is that they stay on their maintenance therapy.” -Dr David Rubin #ACR19 @RheumNow
Maeve Gamble MaeveGamble ( View Tweet)
5 of 6 patients with CRIA (Cleavage-Resistant RIPK1-Induced Autoinflammatory) responded well to tocilizumab. @AmandaOmbrello #ACR19 @rheumnow
Jonathan Hausmann MD hausmannMD ( View Tweet)
occurrence of extra-articulations manifestations is high & increases over time
#ACR19 @rheumnow 4M064 https://t.co/QC62S7cvPk
Dr Irwin Lim _connectedcare ( View Tweet)
If appendix removed by age 25 for true appendicitis, won’t get UC (can still get crohns)...fascinating 🤔 -Dr D Rubin #ACR19 @RheumNow
Maeve Gamble MaeveGamble ( View Tweet)
Holy Molly! TNFi (etanercept, adalimumab, infliximab, or golimumab) completely prevented stokes in patients with DADA2. #ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
#ACR19 @rheumnow ABS1513 Tofacitinib efficacy in PSA ⬇️ if BL BMI ≥ 35 . Safety consistent across all BL BMI categories. 3 CV events: non-fatal cerebrovascular accident, TIA(both Tofa 5 mg BID, BMI ≥ 30 – < 35), and artery revascularization in PBO; BMI ≥ 35 https://t.co/Y8htX6qETV
Olga Petryna DrPetryna ( View Tweet)
#ACR19 @rheumnow abs1913 Cohort study confirms the association of HLA-B*15 with peripheral joint involvement in AS but not in PSA, suggesting different mechanisms may be in play in the pathogenesis of peripheral joint and entheseal involvement between AS &PSA https://t.co/NdaHqI63oH
Olga Petryna DrPetryna ( View Tweet)
@AmandaOmbrello from @NIH_NIAMS at #ACR19 :
#Rheumatologists... Have you come across Adult-Onset Sporadic #PolyarteritisNodosa ?...
🚨 Don’t forget to check for ADA2 mutation!!! 🚨
@ACRheum @RheumNow https://t.co/1MP0wsD6Vr
Adam Kilian MD KilianMD ( View Tweet)
60%
The percentage of patients at @NIH's autoinflammatory disease cohort that are undifferentiated and do not have a specific disease diagnosis -Dr. Amanda Ombrello. #ACR19 @rheumnow https://t.co/d85OtnEA8o
Jonathan Hausmann MD hausmannMD ( View Tweet)
H2H Vedo vs Ada for gut disease (not joint)(no dose escalation in this trial)
#ACR19 @rheumnow 4M064 https://t.co/30JhLETdAK
Dr Irwin Lim _connectedcare ( View Tweet)
Panel on podcasting in rheumatology led by @RheumNow with @AdamJBrownMD @hausmannMD @EBRheum and myself. #ACR19 https://t.co/W1EMXe2qsd
Dr. Paul Sufka psufka ( View Tweet)
Shared & separate targets for autoimmune bowel disease & SpA. Nice summary
#ACR19 @rheumnow 4M064 https://t.co/5Mz7pM0hPv
Dr Irwin Lim _connectedcare ( View Tweet)
Treatment of patients with haploinsufficiency 20 (HA20) responds to HIGH (500mg!) doses of anakinra, TNF inhibitors, or--recently--JAK inhibitors. @AmandaOmbrello #ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
The questions that Dr. Amanda Ombrello (@NIH) asks when evaluating patients with recurrent fevers: -Age of onset -Frequency -Duration -Regularity -Height of fever -Prodromal symptoms #ACR19 @rheumnow
Jonathan Hausmann MD hausmannMD ( View Tweet)
Can lowering #uricacid improve hepatic fibrosis? Dr Naomi Schlesinger presented data from pegloticase #gout studies showing improvement/prevention of worsening vs pbo via the Fib-4 score Changes esp marked in pts with clinically important baseline Fib-4 score @RheumNow #ACR2019 https://t.co/8QUZvlcf57
Gout Study Group GoutGroup ( View Tweet)
PATCH: HCQ reduces congenital heart block (CHB) recurrence in babies born to Ro+ mothers w/ sibilings w/ CHB. This is encouraging data that further supports treatment induction in Ro+ pregnant pts to decrease fetal risk. https://t.co/0uU1zZP80l Plenary abs#1761 #ACR19 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
“It’s so rare that a lupus clinical trial makes it to a plenary session...so cherish the moment!” -Dr Richard Furie on anifrolumab in SLE 🤣 #ACR19 @RheumNow
Maeve Gamble MaeveGamble ( View Tweet)
TULIP1 Anifrolumab RCT in SLE
Did NOT meet primary endpt SIR4 wk52 (36% v 40% PLBO, NS)
Post Hoc BICLA response DID favor Tx (46% v 30%, NNT~6)
Richard Furie: "Medication rules and endpoint selection are critical for SLE trials." Agreed.
#ACR19 Abst#1763 #ACRBest @RheumNow https://t.co/R4ily1Ubrz
Mike Putman EBRheum ( View Tweet)
Neonatal complete heart block is one to avoid. In Ro-pos mothers with a prev child with CHB, HCQ reduces rates from a historic 20% to 7.4% in the PATCH study. It seems we’re yet to fully realize the power of HCQ in conditions like these!
@nyuschoolofmed #ACR19 ABST1761 @RheumNow https://t.co/TMzmq6TjJx
David Liew drdavidliew ( View Tweet)